Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2014

View Archived Issues

CTI BioPharma completes enrollment in phase III myelofibrosis trial of pacritinib

GlycoVaxyn and Janssen initiate phase I trial of extra-intestinal pathogenic E. coli vaccine

Cortex Pharmaceuticals enters an agreement with the University of Illinois

PaxVax reports efficacy results from phase III cholera challenge study

Embera's phase I study of EMB-001 to receive funding from Sounds Affects Life

Novel radiotracer shows potential for PET imaging of LPA-1 receptor expression

Renal benefits reported for VPI-2690B in a model of diabetic nephropathy

Ultragenyx initiates pediatric X-linked hypophosphatemia trial for KRN-23

Presentation of data on Aeolus' AEOL-10150 medical countermeasure

DGAT1 inhibitor protects beta-cell function under nutrient overload

TH-302 enters phase II trial in NSCLC

Enrollment opens in trial of apatorsen and chemotherapy in squamous cell lung cancer

Quark completes study of QPI-1002 to prevent delayed graft function in kidney transplantation

First-in-human evaluation of the safety of an antibody against kidney transplant rejection

Roche prepares new proteasome inhibitors

Researchers at Chiesi Farmaceutici disclose novel PDE4 inhibitors

Antiviral agents patented by Siga Technologies

Japanese researchers divulge novel anti-VASH2 antibodies for cancer

Merck & Co. prepares new HIV vaccines

PKC, a potential target for NAFLD-related hepatic insulin resistance in type 2 diabetes

FDA places clinical hold on phase I trial of TKM-Ebola

FDA grants orphan drug designation to trifarotene for congenital ichthyosis

Eagle Pharmaceuticals gains tentative approval for patented bendamustine injection

First patient enrolled in the PROSPECT II study

FDA approves belinostat for peripheral T-cell lymphoma

Halaven approved in the E.U. for second-line therapy of breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...